FI3577237T3 - Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia - Google Patents
Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia Download PDFInfo
- Publication number
- FI3577237T3 FI3577237T3 FIEP18703944.1T FI18703944T FI3577237T3 FI 3577237 T3 FI3577237 T3 FI 3577237T3 FI 18703944 T FI18703944 T FI 18703944T FI 3577237 T3 FI3577237 T3 FI 3577237T3
- Authority
- FI
- Finland
- Prior art keywords
- pca
- pcags
- prostate cancer
- value
- population
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B10/00—ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Software Systems (AREA)
- Bioethics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Artificial Intelligence (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1750080 | 2017-02-01 | ||
| PCT/EP2018/052473 WO2018141828A1 (en) | 2017-02-01 | 2018-02-01 | Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3577237T3 true FI3577237T3 (fi) | 2023-08-29 |
Family
ID=61188779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18703944.1T FI3577237T3 (fi) | 2017-02-01 | 2018-02-01 | Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190345565A1 (https=) |
| EP (1) | EP3577237B1 (https=) |
| JP (2) | JP7138112B2 (https=) |
| CN (1) | CN110382718A (https=) |
| DK (1) | DK3577237T3 (https=) |
| FI (1) | FI3577237T3 (https=) |
| WO (1) | WO2018141828A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6678201B2 (ja) * | 2018-06-05 | 2020-04-08 | 日清食品ホールディングス株式会社 | 食品情報提供システム、装置、方法及びプログラム |
| GB2599198B (en) * | 2021-06-15 | 2022-12-07 | A3P Biomedical Ab | A method for determining an appropriate time interval for further diagnostic testing for prostate cancer |
| CA3250931A1 (en) * | 2022-04-27 | 2023-11-02 | Rhy Genetype Pty Ltd | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROSTATE CANCER |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| CA2667737A1 (en) * | 2006-10-27 | 2008-05-02 | Julius Gudmundsson | Cancer susceptibility variants on chr8q24.21 |
| WO2010081240A1 (en) | 2009-01-19 | 2010-07-22 | Miraculins Inc. | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| WO2012029080A1 (en) * | 2010-08-30 | 2012-03-08 | Decode Genetics Ehf | Sequence variants associated with prostate specific antigen levels |
| US9732389B2 (en) | 2010-09-03 | 2017-08-15 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| JP2015524052A (ja) * | 2012-05-16 | 2015-08-20 | ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ | 前立腺癌の存在または不存在の提示方法 |
| KR20150110477A (ko) * | 2012-11-20 | 2015-10-02 | 파디아 에이비 | 공격적인 전립선 암의 존재 또는 부존재를 나타내는 방법 |
| ES2694409T3 (es) * | 2012-11-20 | 2018-12-20 | Phadia Ab | Método de pronóstico para individuos con cáncer de próstata |
| AU2015230017B2 (en) * | 2014-03-11 | 2021-06-17 | A3P Biomedical Ab | Method for detecting a solid tumor cancer |
| CN104946786B (zh) * | 2015-07-21 | 2018-02-27 | 冯宁翰 | 一种检测前列腺癌易感性的方法及试剂盒 |
-
2018
- 2018-02-01 JP JP2019541445A patent/JP7138112B2/ja active Active
- 2018-02-01 EP EP18703944.1A patent/EP3577237B1/en active Active
- 2018-02-01 US US16/481,956 patent/US20190345565A1/en not_active Abandoned
- 2018-02-01 WO PCT/EP2018/052473 patent/WO2018141828A1/en not_active Ceased
- 2018-02-01 DK DK18703944.1T patent/DK3577237T3/da active
- 2018-02-01 FI FIEP18703944.1T patent/FI3577237T3/fi active
- 2018-02-01 CN CN201880009454.1A patent/CN110382718A/zh active Pending
-
2022
- 2022-09-05 JP JP2022140682A patent/JP2022179483A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190345565A1 (en) | 2019-11-14 |
| EP3577237B1 (en) | 2023-07-19 |
| JP2020505928A (ja) | 2020-02-27 |
| EP3577237A1 (en) | 2019-12-11 |
| DK3577237T3 (da) | 2023-08-28 |
| CN110382718A (zh) | 2019-10-25 |
| JP2022179483A (ja) | 2022-12-02 |
| JP7138112B2 (ja) | 2022-09-15 |
| WO2018141828A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109859801B (zh) | 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法 | |
| Prensner et al. | RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1 | |
| Sandhu et al. | Panomics for precision medicine | |
| Jeon et al. | Temporal stability and prognostic biomarker potential of the prostate cancer urine miRNA transcriptome | |
| Sung et al. | Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer | |
| Van Laar et al. | Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use | |
| Matsui | Genomic biomarkers for personalized medicine: development and validation in clinical studies | |
| JP2019049559A (ja) | 侵攻性前立腺癌の存在または不存在を判定する方法 | |
| US20150094221A1 (en) | Method for Indicating the Presence or Non-Presence of Prostate Cancer | |
| JP2014533955A (ja) | パクリタキセル応答性がんマーカー | |
| RU2015124008A (ru) | Способ прогноза для индивидуумов с раком предстательной железы | |
| Akamatsu et al. | Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese | |
| FI3577237T3 (fi) | Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia | |
| Viprey et al. | Minimal disease monitoring by QRT–PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials | |
| Greco et al. | HCG18, LEF1AS1 and lncCEACAM21 as biomarkers of disease severity in the peripheral blood mononuclear cells of COVID-19 patients | |
| Cano-Gamez et al. | The circulating cell-free DNA landscape in sepsis is dominated by impaired liver clearance | |
| Allione et al. | Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort | |
| Elamin et al. | A specific blood signature reveals higher levels of S100A12: a potential bladder cancer diagnostic biomarker along with urinary engrailed-2 protein detection | |
| US20190024184A1 (en) | Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers | |
| Huang et al. | Construction and validation of a novel prognostic signature of idiopathic pulmonary fibrosis by identifying subtypes based on genes related to 7-methylguanosine modification | |
| Lu et al. | Transcriptional profiling and co-expression network analysis identifies potential biomarkers to differentiate chronic hepatitis B and the caused cirrhosis | |
| JP2020505928A5 (https=) | ||
| CN115044665A (zh) | Arg1在制备脓毒症诊断、严重程度判断或预后评估试剂或试剂盒中的应用 | |
| Mhatre et al. | The rs10993994 in the proximal MSMB promoter region is a functional polymorphism in Asian Indian subjects | |
| CN113234823A (zh) | 胰腺癌预后风险评估模型及其应用 |